We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Allergan plc | NYSE:AGN | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 193.02 | 0 | 01:00:00 |
TIDM0QCV TIDM0Y7T FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1) State Street Global Advisors & Affiliates --------------------------------------------- ------------------------------- Company dealt in AbbVie Inc. --------------------------------------------- ------------------------------- Class of relevant security to which US$0.01 common stock the dealings being disclosed relate (Note 2) --------------------------------------------- ------------------------------- Date of dealing 14(th) April 2020 --------------------------------------------- ------------------------------- 2. INTERESTS AND SHORT POSITIONS (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) Long Short ------------------------------------- -------------------- ----------- Number (%) Number (%) ------------------------------------- ---------- -------- ------ --- (1) Relevant securities 69,695,919 4.71979% ------------------------------------- ---------- -------- ------ --- (2) Derivatives (other than options) N/A ------------------------------------- ---------- -------- ------ --- (3) Options and agreements to purchase/sell N/A ------------------------------------- ---------- -------- ------ --- Total 69,695,919 4.71979% ------------------------------------- ---------- -------- ------ --- (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) Class of relevant security: Long Short ------------------------------------------- ----------- ----------- Number (%) Number (%) ------------------------------------------- ------ --- ------ --- (1) Relevant securities N/A ------------------------------------------- ------ --- ------ --- (2) Derivatives (other than options) N/A ------------------------------------------- ------ --- ------ --- (3) Options and agreements to purchase/sell N/A ------------------------------------------- ------ --- ------ --- Total N/A ------------------------------------------- ------ --- ------ --- 3. DEALINGS (Note 4) (a) Purchases and sales Purchase/sale Number of relevant securities Price per unit (Note 5) -------------- ----------------------------- ----------------------- Purchase 1,200 82.13 -------------- ----------------------------- ----------------------- Purchase 400 82.13 -------------- ----------------------------- ----------------------- Purchase 32,303 82.13 -------------- ----------------------------- ----------------------- Purchase 1,000 82.13 -------------- ----------------------------- ----------------------- Purchase 4,400 82.13 -------------- ----------------------------- ----------------------- Purchase 300 82.13 -------------- ----------------------------- ----------------------- Purchase 500 82.13 -------------- ----------------------------- ----------------------- Purchase 300 82.13 -------------- ----------------------------- ----------------------- Purchase 400 81.86 -------------- ----------------------------- ----------------------- Purchase 260 82.13 -------------- ----------------------------- ----------------------- Purchase 296,926 82.13 -------------- ----------------------------- ----------------------- Purchase 101,388 82.13 -------------- ----------------------------- ----------------------- Purchase 2,784 82.13 -------------- ----------------------------- ----------------------- Purchase 864 82.13 -------------- ----------------------------- ----------------------- Purchase 325 82.13 -------------- ----------------------------- ----------------------- Purchase 130 82.13 -------------- ----------------------------- ----------------------- Purchase 267 82.13 -------------- ----------------------------- ----------------------- Purchase 564 82.13 -------------- ----------------------------- ----------------------- Purchase 125 81.30 -------------- ----------------------------- ----------------------- Sale 678 82.13 -------------- ----------------------------- ----------------------- Sale 4,400 82.13 -------------- ----------------------------- ----------------------- Sale 1,000 82.13 -------------- ----------------------------- ----------------------- Sale 500 82.13 -------------- ----------------------------- ----------------------- Sale 16,600 82.38 -------------- ----------------------------- ----------------------- Sale 21,900 82.38 -------------- ----------------------------- ----------------------- Sale 4,700 82.13 -------------- ----------------------------- ----------------------- Sale 600 82.13 -------------- ----------------------------- ----------------------- Sale 2,385 82.13 -------------- ----------------------------- ----------------------- Sale 6,270 82.13 -------------- ----------------------------- ----------------------- Sale 1,100 82.13 -------------- ----------------------------- ----------------------- Sale 534 82.13 -------------- ----------------------------- ----------------------- (b) Derivatives transactions (other than options transactions) Product name, Nature of transaction Number of relevant securities Price per unit e.g. CFD (Note 6) (Note 7) (Note 5) ------------- --------------------- ----------------------------- -------------- N/A ------------- --------------------- ----------------------------- -------------- (c) Options transactions in respect of existing relevant securities (i) Writing, selling, purchasing or varying Product name, Writing, selling, Number of Exercise Type, e.g. Expiry Option money e.g. call option purchasing securities to which price American, date paid/received varying etc. the option relates European etc. per unit (Note 5) (Note 7) ----------------- ----------------- -------------------- -------- -------------- ------ ------------------ N/A ----------------- ----------------- -------------------- -------- -------------- ------ ------------------ (ii) Exercising Product name, Number of securities Exercise price per e.g. call option unit (Note 5) ----------------- -------------------- ------------------ N/A ----------------- -------------------- ------------------ (d) Other dealings (including transactions in respect of new securities) (Note 4) Nature of transaction Details Price per unit (Note 8) (if applicable) (Note 5) --------------------- ------- ------------------------- N/A --------------------- ------- ------------------------- 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. ----------------------------------------------------------- N/A ----------------------------------------------------------- Is a Supplemental Form 8 attached? (Note 9) NO ------------------------------------------------------- -----------------
Date of disclosure 15(th) April 2020 ------------------------------------------------------- ----------------- Contact name Lionel Colaco ------------------------------------------------------- ----------------- Telephone number 020 33956098 ------------------------------------------------------- ----------------- If a connected EFM, name of offeree/offeror with which N/A connected ------------------------------------------------------- ----------------- If a connected EFM, state nature of connection (Note N/A 10) ------------------------------------------------------- -----------------
(END) Dow Jones Newswires
April 15, 2020 10:58 ET (14:58 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Allergan Chart |
1 Month Allergan Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions